A cardiothoracic surgical team with UofL Health–Jewish Hospital and the University of Louisville (Louisville, USA) has performed the world’s first Aeson bioprosthetic total artificial heart implantation in a female patient.

Ultrasound-guided transfemoral transcatheter aortic valve implantation (TAVI) is associated with a significant reduction in the risk of access site vascular and bleeding complications, compared to a fluoroscopy-guided strategy, a systematic review and meta-analysis comparing the two approaches has concluded.

One-year data from preclinical trials of Xeltis restorative coronary artery bypass graft (XABG) show that the device remained open to allow blood flow for 12 months in a challenging ovine model. The results were presented by Mohammed El-Kurdi, Xeltis’ vice president for R&D Vascular, at the International Society for Applied Cardiovascular Biology (ISACB 2021, 17–18 September, Atlanta, USA).

European Society of Hypertension (ESH), the leading hypertension (HTN) society in Europe, presented an updated position paper on renal denervation (RDN) during the eighth pre-ESH congress satellite symposium (10–11 September; Athens, Greece). The paper was recently published in the September issue of the Journal of Hypertension.

Peijia Medical has announced the initiation of its multicentre clinical trial for TaurusNXT, the third-generation transcatheter aortic valve implantation (TAVI) system, following the first successful patient implant in Zhongshan Hospital of Fudan University, Shanghai, China.

Peijia Medical has announced the initiation of its multicentre clinical trial for TaurusNXT, the third-generation transcatheter aortic valve implantation (TAVI) system, following the first successful patient implant in Zhongshan Hospital of Fudan University, Shanghai, China.

Four-dimensional (4D) flow magnetic resonance imaging (MRI) has the potential to identify patients with a higher risk of severe complications from aortic degeneration according to research published in JACC: Cardiovascular Imaging. The study employed a 4D flow MRI heatmap concept to detect abnormal aortic wall shear stress, a known stimulus for arterial wall dysfunction.

CytoSorbents has filed an investigational device exemption (IDE) application to gain US Food and Drug Administration (FDA) approval to conduct the clinical study—Safe and timely antithrombotic removal–direct oral anticoagulants (STAR-D)—in the USA to support FDA marketing approval for DrugSorb-ATR antithrombotic removal system. 

STENTiT, a medical device company bringing a novel class of regenerative endovascular implants for treatment of cardiovascular diseases, has announced the appointment of its medical advisory board, chaired by Patrick Serruys (National University of Ireland, Galway, Ireland) and complemented by Marc van Sambeek (Eindhoven University of Technology, Eindhoven, The Netherlands) and Yoshinobu Onuma (National University of Ireland, Galway, Ireland).

Adults younger than 45 years who reported recently using cannabis were two times more likely to have had a myocardial infarction (MI), and this link was stronger in frequent users, according to new research in the Canadian Medical Association Journal (CMAJ).

HeartFlow has announced that physicians at Erasmus MC Hospital (Rotterdam, The Netherlands) have enrolled the first three patients in the FUSION (Addition of FFRct in the diagnostic pathway of patients with stable chest pain to reduce unnecessary invasive coronary angiography) randomised controlled trial.

Findings of the STOPDAPT-2 ACS trial presented during a hot line session at the European Society of Cardiology’s 2021 congress (ESC 2021, 27–30 August, virtual), do not support the use of one month of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients undergoing stent implantation.